WO2011139832A2 - Méthode de traitement des infections mycobactériennes - Google Patents

Méthode de traitement des infections mycobactériennes Download PDF

Info

Publication number
WO2011139832A2
WO2011139832A2 PCT/US2011/034319 US2011034319W WO2011139832A2 WO 2011139832 A2 WO2011139832 A2 WO 2011139832A2 US 2011034319 W US2011034319 W US 2011034319W WO 2011139832 A2 WO2011139832 A2 WO 2011139832A2
Authority
WO
WIPO (PCT)
Prior art keywords
mediated
mycobacterium
compound
tautomer
infection
Prior art date
Application number
PCT/US2011/034319
Other languages
English (en)
Other versions
WO2011139832A3 (fr
Inventor
Joseph A. Devito
Joyce A. Sutcliffe
Original Assignee
Rib-X Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rib-X Pharmaceuticals, Inc. filed Critical Rib-X Pharmaceuticals, Inc.
Publication of WO2011139832A2 publication Critical patent/WO2011139832A2/fr
Publication of WO2011139832A3 publication Critical patent/WO2011139832A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Definitions

  • the present invention relates to methods for treating mycobacterial infections, for example infections caused or mediated by Mycobacterium tuberculosis or nontuberculous mycobacteria and in particular those infections caused or mediated by resistant or highly virulent strains of mycobacteria, using a safe and effective amount of an antibiotic compound or tautomer thereof or a pharmaceutically acceptable salt or prodrug of said compound or tautomer.
  • Tuberculosis is a chronic, infectious disease caused by infection with Mycobacterium tuberculosis (M. tuberculosis). It is a major disease in developing countries, as well as an increasing problem in developed areas of the world, with about 8 million new cases and 3 million deaths each year. Although the infection may be asymptomatic for a considerable period of time, the disease is most commonly manifested as a chronic inflammation of the lungs, resulting in fever and respiratory symptoms. If left untreated, significant morbidity and death can result.
  • Current tuberculosis therapy is primarily based on four drugs, namely isoniazid, rifampin (also known as rifampicin), ethambutol, and pyrazinamide.
  • tuberculosis can generally be controlled, such treatment is not always sufficient to prevent the spread of the disease. Infected individuals may be asymptomatic, but contagious, for some time. Moreover, therapy usually requires long-term treatment (usually six to eight months), often using a combination of two or more drugs, many of which have undesirable toxicities and side effects. Because compliance with the treatment regimen is critical to success, patient behavior is difficult to monitor. Consequently, some patients do not complete the course of therapy, which can lead to ineffective treatment and the development of drug resistant M. tuberculosis strains. The increasing incidence of resistant and highly virulent strains of M. tuberculosis is presenting a further public health concern.
  • Mycobacterium species are also a public health concern.
  • the nontuberculosis mycobacterial species Mycobacterium avium is responsible for causing often serious pulmonary infections, especially in immune-compromised patients such as those infected with HIV.
  • the present invention relates to methods for treating mycobacterial infections, for example infections caused or mediated by Mycobacterium tuberculosis or nontuberculous mycobacteria and in particular those infections caused or mediated by resistant or highly virulent strains of mycobacteria, using a safe and effective amount of an antibiotic compound or tautomer thereof or a pharmaceutically acceptable salt or prodrug of said compound or tautomer.
  • the present invention provides compositions useful in the present invention and provides the use of an antibiotic compound or tautomer thereof or a pharmaceutically acceptable salt or prodrug of said compound or tautomer in the manufacture of a medicament useful for treating mycobacterial infections, for example infections caused or mediated by Mycobacterium tuberculosis or nontuberculous mycobacteria and in particular those infections caused or mediated by resistant or highly virulent strains of mycobacteria.
  • the present invention relates to methods for treating mycobacterial infections, for example infections caused or mediated by Mycobacterium tuberculosis or nontuberculous mycobacteria and in particular those infections caused or mediated by resistant or highly virulent strains of mycobacteria, using a safe and effective amount of an antibiotic compound or tautomer thereof or a pharmaceutically acceptable salt or prodrug of said compound or tautomer.
  • antibiotic compounds can include, for example, oxazolidinone antimicrobial compounds.
  • patient means the human or animal (in the case of an animal, more typically mammals and domestic animals) subject that would be considered to be in need of the methods of treating an infection caused or mediated by Mycobacterium tuberculosis or nontuberculous mycobacteria and in particular those infections caused or mediated by resistant or highly virulent strains of mycobacteria.
  • the phrase "pharmaceutically acceptable” refers to those compounds, materials, compositions, carriers, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • treating means to cure an already present infection caused or mediated by Mycobacterium tuberculosis or nontuberculous mycobacteria and in particular those infections caused or mediated by resistant or highly virulent strains of mycobacteria in a patient or subject.
  • preventing means, to completely or almost completely stop an infection caused or mediated by Mycobacterium tuberculosis or nontuberculous mycobacteria and in particular those infections caused or mediated by resistant or highly virulent strains of mycobacteria from occurring in a patient or subject, especially when the patient or subject is predisposed to such.
  • Preventing can also include inhibiting, i.e. arresting the development of, an infection caused or mediated by Mycobacterium tuberculosis or nontuberculous mycobacteria and in particular those infections caused or mediated by resistant or highly virulent strains of mycobacteria.
  • reducing the risk of means to lower the likelihood or probability of an infection caused or mediated by Mycobacterium tuberculosis or nontuberculous mycobacteria and in particular those infections caused or mediated by resistant or highly virulent strains of mycobacteria from occurring, especially when the patient or subject is predisposed to such occurrence.
  • the term "pharmaceutically effective amount” refers to an amount of a compound or tautomer thereof or a pharmaceutically acceptable salt or prodrug of said compound or tautomer, or a combination of compounds or tautomers, of the present invention effective when administered alone or in combination with other active ingredients are useful to treat, prevent, or reduce the risk of an infection caused or mediated by Mycobacterium tuberculosis or nontuberculous mycobacteria and in particular those infections caused or mediated by resistant or highly virulent strains of mycobacteria.
  • a pharmaceutically effective amount refers to an amount of a compound or tautomer thereof or a pharmaceutically acceptable salt or prodrug of said compound or tautomer, or a combination of compounds or tautomers, of the present invention effective when administered alone or in combination with other active ingredients are useful to treat, prevent, or reduce the risk of an infection caused or mediated by Mycobacterium tuberculosis or nontuberculous mycobacteria and in particular those infections caused or
  • pharmaceutically effective amount refers to an amount of the compound or tautomer thereof or a pharmaceutically acceptable salt or prodrug of said compound or tautomer present in a formulation or on a medical device given to a recipient patient or subject sufficient to elicit biological activity, for example, activity against an infection caused or mediated by
  • the combination of compounds or tautomers thereof or pharmaceutically acceptable salts or prodrugs of said compounds or tautomers optionally is a synergistic combination. Synergy, as described, for example, by Chou and Talalay, Adv. Enzyme Regul. vol. 22, pp. 27-55 (1984), occurs when the effect of the compounds or tautomers thereof or a pharmaceutically acceptable salts or prodrugs of said compounds or tautomers when administered in combination is greater than the additive effect of the compounds when administered alone as a single agent.
  • Synergistic effect is most clearly demonstrated at sub-optimal concentrations of the compounds or tautomers thereof or a pharmaceutically acceptable salts or prodrugs of said compounds or tautomers.
  • Synergy can be in terms of lower cytotoxicity, increased anti-proliferative and/or anti-infective effect, or some other beneficial effect of the combination compared with the individual components.
  • prophylactically effective amount means an effective amount of a compound or tautomer thereof or a pharmaceutically acceptable salt or prodrug of said compound or tautomer (or compounds or tautomers thereof or a pharmaceutically acceptable salts or prodrugs of said compounds or tautomers), of the present invention that is administered to prevent or reduce the risk of an infection caused or mediated by Mycobacterium tuberculosis or nontuberculous mycobacteria and in particular those infections caused or mediated by resistant or highly virulent strains of mycobacteria - in other words, an amount to needed provide a preventative or prophylactic effect.
  • infection has some connection, relation, or etiology to the designated microorganism, i.e. Mycobacterium tuberculosis or nontuberculous mycobacteria and in particular those infections caused or mediated by resistant or highly virulent strains of mycobacteria.
  • topical and “topically” means that the antibiotic compounds or tautomers thereof or pharmaceutically acceptable salts or prodrugs of said compounds or tautomers of the present invention can alternatively be administered or applied to the skin of the patient or subject, or to other non-internal organs or parts of the patient or subject including, for example, the hair, fur, feathers, scales, shells, eyes, and ears.
  • the chemical compounds or tautomers thereof or pharmaceutically acceptable salts or prodrugs of said compounds or tautomers described herein can have asymmetric centers.
  • Cis and trans geometric isomers of the compounds or tautomers thereof or pharmaceutically acceptable salts or prodrugs of said compounds or tautomers of the present invention are described and can be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic, and geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated. All processes used to prepare compounds or tautomers thereof or pharmaceutically acceptable salts or prodrugs of said compounds or tautomers of the present invention and intermediates made therein are, where appropriate, considered to be part of the present invention. All tautomers of shown or described compounds are also, where appropriate, considered to be part of the present invention.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds or tautomers thereof wherein the parent compound or tautomer thereof is modified by making acid or base salts thereof.
  • pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines, alkali or organic salts of acidic residues such as carboxylic acids, and the like.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound or tautomer thereof formed, for example, from non-toxic inorganic or organic acids.
  • such conventional non-toxic salts include, but are not limited to, those derived from inorganic and organic acids selected from 2-acetoxybenzoic, 2-hydroxyethane sulfonic, acetic, ascorbic, benzene sulfonic, benzoic, bicarbonic, carbonic, citric, edetic, ethane disulfonic, ethane sulfonic, fumaric, glucohep tonic, gluconic, glutamic, N-methyl glutamic acid (i.e.
  • glycolic glycollyarsanilic, hexylresorcinic, hydrabamic, hydrobromic, hydrochloric, hydroiodic, hydroxymaleic, hydroxynaphthoic, isethionic, lactic, lactobionic, lauryl sulfonic, maleic, malic, mandelic, methane sulfonic, napsylic, nitric, oxalic, pamoic, pantothenic, phenylacetic, phosphoric, polygalacturonic, propionic, salicylic, stearic, subacetic, succinic, sulfamic, sulfanilic, sulfuric, tannic, tartaric, toluene sulfonic, and the commonly occurring amine acids, e.g., glycine, alanine, phenylalanine, arginine, etc.
  • amine acids e.g., glycine, alanine,
  • the pharmaceutically acceptable salts of the present invention can be synthesized from a parent compound or tautomer thereof that contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds or tautomers thereof with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 18th ed. (Mack Publishing Company, 1990).
  • salts can include, but are not limited to, the hydrochloride and acetate salts of the aliphatic amine-containing, hydroxyl amine-containing, and imine-containing compounds or tautomers thereof or pharmaceutically acceptable salts or prodrugs of said compounds or tautomers of the present invention.
  • the compounds or tautomers thereof or pharmaceutically salts or prodrugs of said compound or tautomers of the present invention can exist in either hydrated or unhydrated (the anhydrous) form or as solvates with other solvent molecules.
  • hydrates include monohydrates, dihydrates, etc.
  • solvates include ethanol solvates, acetone solvates, etc.
  • the compounds or tautomers thereof or pharmaceutically acceptable salts of said compounds or tautomers of the present invention can also be prepared as prodrugs, for example pharmaceutically acceptable prodrugs. Since prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (e.g., solubility, bioavailability, manufacturing, etc.) the compounds or tautomers thereof or pharmaceutically acceptable salts of said compounds or tautomers of the present invention can be delivered in prodrug form. Thus, the present invention is intended to cover prodrugs of the presently claimed compounds or tautomers thereof or pharmaceutically acceptable salts of said compounds or tautomers, methods of delivering the same and compositions containing the same.
  • Prodrugs are intended to include any covalently bonded carriers that release an active parent drug of the present invention in vivo when such prodrug is administered to a mammalian subject.
  • Prodrugs the present invention are prepared by modifying functional groups present in the compound or tautomer thereof or a pharmaceutically acceptable salt thereof in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound or tautomer thereof or pharmaceutically acceptable salt of said compound or tautomer.
  • Prodrugs include compounds or tautomers thereof or pharmaceutically acceptable salts of the present invention wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug of the present invention is administered to a mammalian subject, cleaves to form a free hydroxyl, free amino, or free sulfhydryl group, respectively.
  • Examples of prodrugs include, but are not limited to, acetate, formate, and benzoate derivatives of alcohol and amine functional groups in the compounds or tautomers thereof or pharmaceutically acceptable salts of the present invention.
  • Solid compound and “stable structure” are meant to indicate a compound or tautomer thereof or pharmaceutically acceptable salt or prodrug of said compound or tautomer that is sufficiently robust to survive isolation, and as appropriate, purification from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • MIC minimum inhibitory concentration
  • MCC is minimum bactericidal concentration.
  • MABA mycobacterial alamar blue assay
  • MTB Mycobacterium tuberculosis
  • DMSO dimethylsulfoxide
  • GKO gamma-interferon knockout
  • CCSI Clinical and Laboratory Standards Institute
  • PA-824" is (65)-2-nitro-6- ⁇ [4-(trifluoromethoxy)benzyl]oxy ⁇ -6,7-dihydro-5H-imidazo[2,l- &][l,3]oxazine:
  • TMC207 is (l «,25')-l-(6-bromo-2-methoxy-3-quinolyl)-4-dimethylamino-2-(l-naphthyl)-l- phenyl-butan-2-ol:
  • compositions are described as having, including, or comprising specific components, it is contemplated that compositions also consist essentially of, or consist of, the recited components. Similarly, where methods or processes are described as having, including, or comprising specific process steps, the processes also consist essentially of, or consist of, the recited processing steps. Further, it should be understood that the order of steps or order for performing certain actions is immaterial so long as the invention remains operable. Moreover, two or more steps or actions can be conducted simultaneously. 2.
  • the present invention relates to a method of treating a mycobacterial infection, for example an infection caused or mediated by Mycobacterium tuberculosis or a nontuberculous mycobacterium and in particular an infection caused or mediated by a resistant or highly virulent strain of a mycobacterium, in a patient comprising administering a pharmaceutically effective amount of an antibiotic compound or tautomer thereof or pharmaceutically acceptable salt or prodrug of said compound or tautomer to a patient.
  • a mycobacterial infection for example an infection caused or mediated by Mycobacterium tuberculosis or a nontuberculous mycobacterium and in particular an infection caused or mediated by a resistant or highly virulent strain of a mycobacterium
  • the present invention relates to a method of preventing a mycobacterial infection, for example an infection caused or mediated by Mycobacterium tuberculosis or a nontuberculous mycobacterium and in particular an infection caused or mediated by a resistant or highly virulent strain of a mycobacterium, in a patient comprising administering a prophylactically effective amount of an antibiotic compound or tautomer thereof or pharmaceutically acceptable salt or prodrug of said compound or tautomer to a patient.
  • a mycobacterial infection for example an infection caused or mediated by Mycobacterium tuberculosis or a nontuberculous mycobacterium and in particular an infection caused or mediated by a resistant or highly virulent strain of a mycobacterium
  • the present invention relates to a method of reducing the risk of a mycobacterial infection, for example an infection caused or mediated by Mycobacterium tuberculosis or a nontuberculous mycobacterium and in particular an infection caused or mediated by a resistant or highly virulent strain of a mycobacterium, in a patient comprising administering a
  • the present invention relates to a method, wherein the infection is caused or mediated by Mycobacterium tuberculosis. In one aspect, the infection is caused or mediated by a nontuberculous mycobacterium.
  • the present invention relates to a composition for treating a mycobacterial infection, for example an infection caused or mediated by Mycobacterium tuberculosis or a nontuberculous mycobacterium and in particular an infection caused or mediated by a resistant or highly virulent strain of a mycobacterium, in a patient comprising a pharmaceutically effective amount of an antibiotic compound or tautomer thereof or pharmaceutically acceptable salt or prodrug of said compound or tautomer.
  • the present invention relates to a composition for preventing a mycobacterial infection, for example an infection caused or mediated by Mycobacterium tuberculosis or a nontuberculous mycobacterium and in particular an infection caused or mediated by a resistant or highly virulent strain of a mycobacterium, in a patient comprising a prophylactically effective amount of an antibiotic compound or tautomer thereof or pharmaceutically acceptable salt or prodrug of said compound or tautomer.
  • the present invention relates to a composition for reducing the risk of a mycobacterial infection, for example an infection caused or mediated by Mycobacterium tuberculosis or a nontuberculous mycobacterium and in particular an infection caused or mediated by a resistant or highly virulent strain of a mycobacterium, in a patient comprising a prophylactically effective amount of an antibiotic compound or tautomer thereof or pharmaceutically acceptable salt or prodrug of said compound or tautomer.
  • the present invention relates to a composition, where in the infection is caused or mediated by Mycobacterium tuberculosis. In one aspect, the infection is caused or mediated by a nontuberculous mycobacterium.
  • the present invention relates to a use of an antibiotic compound or tautomer thereof or pharmaceutically acceptable salt or prodrug of said compound or tautomer in the manufacture of a medicament for treating a mycobacterial infection, for example an infection caused or mediated by Mycobacterium tuberculosis or a nontuberculous mycobacterium and in particular an infection caused or mediated by a resistant or highly virulent strain of a mycobacterium, in a patient comprising administering a pharmaceutically effective amount of an antibiotic compound or tautomer thereof or pharmaceutically acceptable salt or prodrug of said compound or tautomer to a patient.
  • a mycobacterial infection for example an infection caused or mediated by Mycobacterium tuberculosis or a nontuberculous mycobacterium and in particular an infection caused or mediated by a resistant or highly virulent strain of a mycobacterium
  • the present invention relates to a use of an antibiotic compound or tautomer thereof or pharmaceutically acceptable salt or prodrug of said compound or tautomer in the manufacture of a medicament for preventing a mycobacterial infection, for example an infection caused or mediated by Mycobacterium tuberculosis or a nontuberculous mycobacterium and in particular an infection caused or mediated by a resistant or highly virulent strain of a mycobacterium, in a patient comprising administering a prophylactically effective amount of an antibiotic compound or tautomer thereof or pharmaceutically acceptable salt or prodrug of said compound or tautomer to a patient.
  • a mycobacterial infection for example an infection caused or mediated by Mycobacterium tuberculosis or a nontuberculous mycobacterium and in particular an infection caused or mediated by a resistant or highly virulent strain of a mycobacterium
  • the present invention relates to a use of an antibiotic compound in the manufacture of a medicament for reducing the risk of a mycobacterial infection, for example an infection caused or mediated by Mycobacterium tuberculosis or a nontuberculous mycobacterium and in particular an infection caused or mediated by a resistant or highly virulent strain of a mycobacterium, in a patient comprising administering a prophylactically effective amount of an antibiotic compound or tautomer thereof or pharmaceutically acceptable salt or prodrug of said compound or tautomer to a patient.
  • the present invention relates to a use, wherein the infection is caused or mediated by Mycobacterium tuberculosis. In another aspect, the infection is caused or mediated by a nontuberculous mycobacterium.
  • the present invention relates to a method, composition, or use, wherein the patient is a mammal or a domestic animal. In one aspect, the patient is a human.
  • the present invention relates to a method, composition, or use, wherein the antibiotic compound or tautomer thereof or pharmaceutically acceptable salt or prodrug of said compound or tautomer is administered orally.
  • the antibiotic compound or tautomer thereof or pharmaceutically acceptable salt or prodrug of said compound or tautomer is administered via inhalation.
  • the antibiotic compound or tautomer thereof or pharmaceutically acceptable salt or prodrug of said compound or tautomer is administered topically.
  • the antibiotic compound or tautomer thereof or pharmaceutically acceptable salt or prodrug of said compound or tautomer is administered parenterally.
  • the antibiotic compound or tautomer thereof or pharmaceutically acceptable salt or prodrug of said compound or tautomer is administered intravenously.
  • the present invention relates to a method, composition, or use, wherein the antibiotic compound or tautomer thereof or pharmaceutically acceptable salt or prodrug of said compound or tautomer is selected from an oxazolidinone antibiotic compound.
  • the antibiotic compound is or a tautomer thereof or a pharmaceutically acceptable salt or prodrug said compound or tautomer.
  • the present invention relates to the method, composition, or use, wherein said antibiotic compound is a non-toxic inorganic or organic acid salt.
  • the present invention relates to the method, composition, or use, wherein the non-toxic inorganic or organic acid salt is selected from 2-acetoxybenzoic, 2-hydroxyethane sulfonic, acetic, ascorbic, benzene sulfonic, benzoic, bicarbonic, carbonic, citric, edetic, ethane disulfonic, ethane sulfonic, fumaric, glucoheptonic, gluconic, glutamic, glycolic, glycollyarsanilic, hexylresorcinic, hydrobromic, hydrochloric, hydroiodic, hydroxymaleic, hydroxynaphthoic, lactic, lactobionic, lauryl sulfonic, maleic, malic, mandelic, methane sulfonic, napsy
  • the present invention relates to a method, composition or use, further comprising an additional pharmaceutical compound or salt thereof, particularly, one or more compounds typically used for treating, preventing, or reducing the risk of an infection caused or mediated by Mycobacterium tuberculosis or a nontuberculous mycobacterium and in particular those infections caused or mediated by resistant or highly virulent strain of a mycobacterium.
  • the present invention relates to a method, composition, or use, wherein the infection is caused or mediated by Mycobacterium tuberculosis.
  • the infection is caused or mediated by a nontuberculous mycobacterium.
  • the present invention relates to a method, composition or use, further comprising one or more compounds selected from the group consisting of isoniazid, rifampin, rifapentine, rifabutin, ethambutol, pyrazinamide, cycloserine, ethionamide, levofloxacin, moxifloxacin, delafloxacin, nitroimidazoles like PA-824, mycobacterial gyrase inhibitors outside the quinolone class, riminophenazines, InhA inhibitors distinct from isoniazid, new generation diarylquinolines like TMC207, LeuRS inhibitors, tryptanthrins, inhibitors of mycobacterial glyoxylate pathway, non-rifamycin inhibitors of RNA polymerase, menaquinone biosynthesis inhibitors, topoisomerase I inhibitors, mycobacteterial protease inhibitors, gatifloxacin, p- aminosalicylic acid,
  • the present invention relates to a method, composition or use, wherein the infection is caused or mediated by Mycobacterium tuberculosis and in particular an infection caused or mediated by a resistant or highly virulent strain of a mycobacterium, wherein the antibiotic compound is:
  • the present invention relates to a method, composition, or use comprising administering to a patient in need thereof a safe and effective amount of an antibiotic compound or tautomer thereof or a pharmaceutically acceptable salt or prodrug of said compound or tautomer.
  • nontuberculous mycobacteria examples include, inter alia, Mycobacterium avium (also MAC which is referred to as mycobacterial avium complex which is a combination of strains), Mycobacterium intracellular, MAC, Mycobacterium chelonae, Mycobacterium abscessus, Mycobacterium fortuitum, Mycobacterium terrae, Mycobacterium xenopi,
  • Mycobacterium simiae Mycobacterium marinum
  • Mycobacterium szulgai Mycobacterium malmoense.
  • the antibiotic compounds or tautomers thereof or pharmaceutically acceptable salts or prodrugs of said compounds or tautomers of the present invention are useful for treating, preventing, or reducing the risk of these microbial infections.
  • the methods of the present invention can be usefully applied to patients, whether human or animal. More particularly it is found that the antibiotic agents useful herein generally are effective against the mycobacterial microorganisms of interest at relatively low concentrations, i.e. the compounds are relatively potent. Consequently, these compounds or tautomers thereof or pharmaceutically acceptable salts or prodrugs of said compounds or tautomers of the present invention have the potential advantage during administration of less undesired side effects and toxicities and undesired drug-drug interactions.
  • This potential advantage can in turn mean that the compounds or tautomers thereof or pharmaceutically acceptable salts or prodrugs of said compounds or tautomers of the present invention can be administered for relatively long durations and in combination with other agents. Therefore, the methods, compositions, and uses of the present invention have the potential for better safety, efficacy, and patient compliance relative to currently available therapies.
  • the tissue and or blood level in the patient or subject, of the compound or tautomer thereof or pharmaceutically acceptable salt or prodrug of said compound or tautomer used to provide the effect be of an appropriate level for a sufficient time interval. Also, because it often takes a finite amount of time to achieve such blood or tissue levels, it is important that the compound or tautomer thereof or pharmaceutically acceptable salt or prodrug of said compound or tautomer is administered at some appropriate time.
  • the appropriate time for administration of the compound or tautomer thereof or pharmaceutically acceptable salt or prodrug of said compound or tautomer will depend upon the pharmacokinetic profile of the compound or tautomer thereof or pharmaceutically acceptable salt or prodrug of said compound or tautomer and its formulation, route of administration, time required for completing administration, patient characteristics, desired clinical outcome, etc.
  • the antibiotic i.e. antimicrobial compounds or antibiotic agents useful herein are those that are particularly effective against infections caused or mediated by Mycobacterium tuberculosis or nontuberculous mycobacteria and in particular those infections caused or mediated by resistant or highly virulent strains of mycobacteria.
  • antibiotic compounds or tautomers thereof or pharmaceutically acceptable salts or prodrugs of said compounds or tautomers can be used in the methods, compositions, and uses of the present invention.
  • These antibiotic compounds or tautomers thereof or pharmaceutically acceptable salts or prodrugs of said compounds or tautomer scan provide their therapeutic effect by a variety of biochemical or biophysical mechanisms.
  • Antibiotic compounds or tautomers thereof or pharmaceutically acceptable salts or prodrugs of said compounds or tautomers useful in the present invention can include those which bind to or modulate ribosomal RNA, for example bacterial ribosomal RNA.
  • Antibiotic compounds or tautomers thereof or pharmaceutically acceptable salts or prodrugs of said compounds or tautomers also useful in the present invention can include those which bind to or modulate the large ribosomal subunit, for example the large ribosomal subunit of a bacterial organism.
  • Nonlimiting classes of antibiotic compounds useful herein include oxazolidinone antibiotics.
  • Oxazolidinone antibiotics are characterized in having an oxazolidinone ring.
  • the antibiotic compounds useful in the present invention can include their
  • the invention further provides methods for synthesizing any one of the antibiotic compounds or tautomers thereof or pharmaceutically acceptable salts or prodrugs of said compounds or tautomers of the present invention.
  • the invention also provides pharmaceutical compositions comprising an effective amount of one or more of the antibiotic compounds or tautomers thereof or pharmaceutically acceptable salts or prodrugs of said compounds or tautomers of the present invention and a pharmaceutically acceptable carrier.
  • the present invention further provides methods for making these pharmaceutical compositions.
  • Oxazolidinone antimicrobial compounds or tautomers thereof and their pharmaceutically acceptable salts, esters, and prodrugs thereof, can be used in the methods, compositions, and uses of the present invention.
  • Oxazolidinone antimicrobial compounds are described in U.S. Patent No. 7,456,206 B2, to Lou et al., issued November 25, 2008; U.S. Patent No. 7,148,219 B2, to Lou et al., issued December 12, 2006, and its certification of correction of March 4, 2008; U.S. Patent No.
  • Nonlimiting examples of oxazolidione antimicrobial agents useful herein include the following compound:
  • salts include the hydrochloride salt.
  • a further example of a salt is the monohydrochloride salt.
  • the foregoing compound corresponds to the chemical name, inter alia, N-[3-(2-Fluoro-4'- ⁇ [(3H-[l,2,3]triazol-4-ylmethyl)-amino]-methyl ⁇ -biphenyl-4-yl)-2-oxo- oxazolidin-5-(S)-ylmethyl]-acetamide.
  • This compound is also known by the USAN, radezolid, and corresponds to the CAS registry number 869884-78-6.
  • the monohydrochloride salt is known by the USAN, radezolid hydrochloride, and to the CAS registry number 869884-77-5.
  • oxazolidinone antimicrobial compounds useful herein include linezolid and torezolid.
  • antibiotic compounds useful herein and their pharmaceutically salts, esters, tautomers, and prodrugs thereof are disclosed in the documents cited in Table 1. These documents and their disclosures are incorporated by reference herein in their entirety.
  • the dose of the oxazolidinone antimicrobial agent and mode of administration of the pharmaceutical composition will depend upon the intended patient or subject and the targeted microorganism, e.g., the target bacterial organism.
  • Nonlimiting examples of oxazolidione antimicrobial agents useful herein include the following compound:
  • salts include the hydrochloride salt.
  • a further example of a salt is the monohydrochloride salt.
  • the foregoing compound corresponds to the chemical name, inter alia, N-[3-(2-Fluoro-4'- ⁇ [(3H-[l,2,3]triazol-4- ylmethyl)-amino]-methyl ⁇ -biphenyl-4-yl)-2-oxo-oxazolidin-5-(S)-ylmethyl]-acetamide.
  • This compound is also known by the USAN, radezolid, and corresponds to the CAS registry number 869884-78-6.
  • the monohydrochloride salt is known by the USAN, radezolid hydrochloride, and to the CAS registry number 869884-77-5.
  • the oxazolidinone antimicrobial agent is used in a weight percentage in the composition to provide the desired pharmacological properties, such as e.g. drug bioavailability from the final composition.
  • Weight percentages of the oxazolidinone antimicrobial agent range from about 0.01% to about 5%. In further embodiments, weight percentages range from about 0.1% to about 0.5%. In further embodiments, weight percentages range from about 0.25% to about 0.40%.
  • Antibiotic compounds or tautomers thereof or pharmaceutically acceptable salts or prodrugs of said compounds or tautomers designed, selected and/or optimized for use in the present invention, after being produced, can be characterized using a variety of assays known to those skilled in the art to determine whether the compounds or tautomers thereof or
  • antibiotic compounds or tautomers thereof or pharmaceutically acceptable salts or prodrugs of said compounds or tautomers can be characterized by
  • high-throughput screening can be used to speed up analysis using such assays.
  • it can be possible to screen rapidly the molecules described herein for activity, for example as anti-bacterial.
  • it can be possible to assay how the compounds or tautomers thereof or pharmaceutically acceptable salts or prodrugs of said compounds or tautomers interact with a ribosome or ribosomal subunit and/or are effective as modulators (for example, inhibitors) of protein synthesis using techniques known in the art.
  • High-throughput assays can use one or more different assay techniques including, but not limited to, those described below.
  • SPR surface plasmon resonance
  • SPR methodologies measure the interaction between two or more macromolecules in real-time through the generation of a quantum-mechanical surface plasmon.
  • One device (BIAcore Biosensor RTM from Pharmacia Biosensor, Piscataway, N.J.) provides a focused beam of polychromatic light to the interface between a gold film (provided as a disposable biosensor "chip") and a buffer compartment that can be regulated by the user.
  • a 100 nm thick "hydrogel” composed of carboxylated dextran that provides a matrix for the covalent immobilization of analytes of interest is attached to the gold film. When the focused light interacts with the free electron cloud of the gold film, plasmon resonance is enhanced.
  • the resulting reflected light is spectrally depleted in wavelengths that optimally evolved the resonance.
  • the BIAcore establishes an optical interface which accurately reports the behavior of the generated surface plasmon resonance.
  • the plasmon resonance and thus the depletion spectrum
  • the plasmon resonance is sensitive to mass in the evanescent field (which corresponds roughly to the thickness of the hydrogel).
  • the interaction between the two components can be measured in real time based on the accumulation of mass in the evanescent field and its corresponding effects of the plasmon resonance as measured by the depletion spectrum.
  • This system permits rapid and sensitive real-time measurement of the molecular interactions without the need to label either component.
  • Fluorescence polarization is a measurement technique that can readily be applied to protein-protein, protein-ligand, or RNA-ligand interactions in order to derive IC5 0 S and Kds of the association reaction between two molecules.
  • one of the molecules of interest is conjugated with a fluorophore. This is generally the smaller molecule in the system (in this case, the compound of interest).
  • the sample mixture containing both the ligand-probe conjugate and the ribosome, ribosomal subunit or fragment thereof, is excited with vertically polarized light. Light is absorbed by the probe fluorophores, and re-emitted a short time later. The degree of polarization of the emitted light is measured.
  • Polarization of the emitted light is dependent on several factors, but most importantly on viscosity of the solution and on the apparent molecular weight of the fluorophore. With proper controls, changes in the degree of polarization of the emitted light depends only on changes in the apparent molecular weight of the fluorophore, which in-turn depends on whether the probe-ligand conjugate is free in solution, or is bound to a receptor. Binding assays based on FP have a number of important advantages, including the measurement of IC5 0 S and Kds under true homogenous equilibrium conditions, speed of analysis and amenity to automation, and ability to screen in cloudy suspensions and colored solutions.
  • the compound of interest can also be characterized as a modulator (for example, an inhibitor of protein synthesis) of the functional activity of the ribosome or ribosomal subunit.
  • a modulator for example, an inhibitor of protein synthesis
  • more specific protein synthesis inhibition assays can be performed by administering the compound to a whole organism, tissue, organ, organelle, cell, a cellular or subcellular extract, or a purified ribosome preparation and observing its pharmacological and inhibitory properties by determining, for example, its inhibition constant (IC 50 ) for inhibiting protein synthesis.
  • IC 50 inhibition constant
  • Incorporation of 3 H leucine or 35 S methionine, or similar experiments can be performed to investigate protein synthesis activity.
  • a change in the amount or the rate of protein synthesis in the cell in the presence of a molecule of interest indicates that the molecule is a modulator of protein synthesis.
  • a decrease in the rate or the amount of protein synthesis indicates that the molecule is a inhibitor of protein synthesis.
  • antibiotic compounds or tautomers thereof or pharmaceutically acceptable salts or prodrugs of said compounds or tautomers can be assayed for anti-proliferative or anti-infective properties on a cellular level.
  • the target organism is a microorganism
  • the activity of compounds of interest can be assayed by growing the target organism
  • microorganisms of interest in media either containing or lacking the compound. Growth inhibition can be indicative that the molecule could be acting as a protein synthesis inhibitor. More specifically, the activity of the compounds of interest against bacterial pathogens can be demonstrated by the ability of the compound to inhibit growth of defined strains of human pathogens, particularly P. acnes and P. granulosum and resistant strains thereof.
  • a panel of bacterial strains can be assembled to include a variety of target pathogenic species, some containing resistance mechanisms that have been characterized. Use of such a panel of organisms permits the determination of structure- activity relationships not only in regards to potency and spectrum, but also with a view to obviating resistance mechanisms.
  • the assays can be performed in microtiter trays according to conventional methodologies as published by The National Committee for Clinical Laboratory Standards (NCCLS) guidelines (NCCLS. M7-A5-Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Fifth Edition. NCCLS Document M100-S12/M7 (ISBN 1-56238-394-9)).
  • the methods of the present invention can be practiced by delivering the antibiotic compounds or tautomers thereof or pharmaceutically acceptable salts or prodrugs of said compounds or tautomers of the present invention using any suitable carrier.
  • the dose of antibiotic compound or tautomer thereof or pharmaceutically acceptable salt or prodrug of said compound or tautomer, mode of administration and use of suitable carrier will depend upon the intended patient or subject and the targeted microorganism, e.g., the target bacterial organism.
  • the formulations, both for human medical use and veterinary use, of the antibiotic compounds or tautomers thereof or pharmaceutically acceptable salts or prodrugs of said compounds or tautomers according to the present invention typically include such antibiotic compounds or tautomers thereof or pharmaceutically acceptable salts or prodrugs of said compounds or tautomers in association with a pharmaceutically acceptable carrier.
  • the carrier(s) should be "acceptable” in the sense of being compatible with compounds or tautomers thereof or pharmaceutically acceptable salts or prodrugs of said compounds or tautomers of the present invention and not deleterious to the recipient.
  • Pharmaceutically acceptable carriers are intended to include any and all solvents, dispersion media, coatings, absorption delaying agents, and the like, compatible with pharmaceutical
  • compositions can conveniently be presented in dosage unit form and can be prepared by any of the methods well known in the art of pharmacy/microbiology.
  • some formulations are prepared by bringing the compound or tautomer thereof or a pharmaceutically acceptable salt or prodrug of said compound or tautomer into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation.
  • a pharmaceutical composition of the invention can be formulated to be compatible with its intended route of administration. These can include solids and semisolids. Solutions or suspensions can include the following components: a sterile diluent such as water, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • the pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
  • Useful solutions for oral or parenteral administration can be prepared by any of the methods well known in the pharmaceutical art, described, for example, in Remington 's
  • Formulations for parenteral administration can also include glycocholate for buccal administration,
  • methoxysalicylate for rectal administration or citric acid for vaginal administration.
  • the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • Suppositories for rectal administration also can be prepared by mixing the drug with a non-irritating excipient such as cocoa butter, other glycerides, or other compositions which are solid at room temperature and liquid at body temperatures.
  • Formulations also can include, for example, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, and hydrogenated naphthalenes.
  • Formulations for direct administration can include glycerol and other compositions of high viscosity.
  • Other potentially useful parenteral carriers for these drugs include ethylene- vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes.
  • Formulations for inhalation administration can contain as excipients, for example, lactose, or can be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or oily solutions for administration in the form of nasal drops, or as a gel to be applied intranasally.
  • Retention enemas also can be used for rectal delivery.
  • Formulations of the present invention suitable for oral administration can be in the form of: discrete units such as capsules, gelatin capsules, sachets, tablets, troches, or lozenges, each containing a predetermined amount of the drug; a powder or granular composition; a solution or a suspension in an aqueous liquid or non-aqueous liquid; or an oil-in-water emulsion or a water- in-oil emulsion.
  • the drug can also be administered in the form of a bolus, electuary or paste.
  • a tablet can be made by compressing or molding the drug optionally with one or more accessory ingredients.
  • Compressed tablets can be prepared by compressing, in a suitable machine, the drug in a free-flowing form such as a powder or granules, optionally mixed by a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets can be made by molding, in a suitable machine, a mixture of the powdered drug and suitable carrier moistened with an inert liquid diluent.
  • Oral compositions generally include an inert diluent or an edible carrier.
  • an inert diluent for the purpose of oral therapeutic administration, the active compound or tautomer thereof or a
  • compositions prepared using a fluid carrier for use as a mouthwash include the compound or tautomer thereof or a pharmaceutically acceptable salt or prodrug of said compound or tautomer in the fluid carrier and are applied orally and swished and expectorated or swallowed.
  • Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
  • the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as
  • microcrystalline cellulose, gum tragacanth or gelatin an excipient such as starch or lactose; a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). It should be stable under the conditions of manufacture and storage and should be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol), and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • isotonic agents for example, sugars, polyalcohols such as manitol, sorbitol, or sodium chloride in the composition.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions can be prepared by incorporating the active compound or tautomer thereof or a pharmaceutically acceptable salt or prodrug of said compound or tautomer in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filter sterilization.
  • dispersions are prepared by incorporating the active compound or tautomer thereof or a pharmaceutically acceptable salt or prodrug of said compound or tautomer into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above.
  • methods of preparation include vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • Formulations suitable for intra-articular administration can be in the form of a sterile aqueous preparation of the drug that can be in microcrystalline form, for example, in the form of an aqueous microcrystalline suspension.
  • Liposomal formulations or biodegradable polymer systems can also be used to present the drug for both intra-articular and ophthalmic
  • Formulations suitable for topical administration include liquid or semi-liquid preparations such as liniments, lotions, gels, applicants, oil-in-water or water-in- oil emulsions such as creams, ointments or pastes; or solutions or suspensions such as drops.
  • Formulations for topical administration to the skin surface can be prepared by dispersing the drug with a dermatologically acceptable carrier such as a lotion, cream, ointment or soap.
  • a dermatologically acceptable carrier such as a lotion, cream, ointment or soap.
  • the agent can be dispersed in a liquid tissue adhesive or other substance known to enhance adsorption to a tissue surface.
  • tissue-coating solutions such as pectin-containing formulations can be used.
  • the carrier for a topical formulation can be in the form of a hydroalcoholic system (e.g. quids and gels), an anhydrous oil or silicone based system, or an emulsion system, including, but not limited to, oil-in-water, water-in-oil, water-in-oil-in-water, and oil-in-water-in- silicone emulsions.
  • a hydroalcoholic system e.g. quids and gels
  • an anhydrous oil or silicone based system emulsion system
  • emulsion system including, but not limited to, oil-in-water, water-in-oil, water-in-oil-in-water, and oil-in-water-in- silicone emulsions.
  • the emulsions can cover a broad range of consistencies including thin lotions (which can also be suitable for spray or aerosol delivery), creamy lotions, light creams, heavy creams, and the like.
  • the emulsions can also include microemulsion systems.
  • topical carriers include anhydrous solids and semisolids (such as gels and sticks); and aqueous based mousse systems.
  • topical carrier systems useful in the present invention are described in the following four references, all of which are incorporated herein by reference in their entirety: "Sun Products Formulary”, Cosmetics & Toiletries, vol. 105, pp. 122-139 (December 1990); “Sun Products Formulary”, Cosmetics & Toiletries, vol. 102, pp. 117-136 (March 1987); U.S. Pat. No. 4,960,764 to Figueroa et al., issued Oct. 2, 1990; and U.S. Pat. No. 4,254,105 to Fukuda et al., issued Mar. 3, 1981.
  • the pharmaceutically-acceptable topical carriers typically comprise from about 0.1% to about 99.8% by weight of the compositions useful in the present invention, preferably from about 80% to about 99%, and most preferably from about 85% to about 95%.
  • inhalation of powder (self-propelling or spray formulations) dispensed with a spray can a nebulizer, or an atomizer can be used.
  • Such formulations can be in the form of a fine powder for pulmonary administration from a powder inhalation device or self- propelling powder-dispensing formulations.
  • self-propelling solution and spray formulations the effect can be achieved either by choice of a valve having the desired spray characteristics (i.e., being capable of producing a spray having the desired particle size) or by incorporating the active ingredient as a suspended powder in controlled particle size.
  • the compounds or tautomers thereof or a pharmaceutically acceptable salts or prodrugs of said compounds or tautomers also can be delivered in the form of an aerosol spray from pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
  • a suitable propellant e.g., a gas such as carbon dioxide, or a nebulizer.
  • Systemic administration also can be by transmucosal or transdermal means.
  • penetrants appropriate to the barrier to be permeated are used in the formulation.
  • penetrants generally are known in the art, and include, for example, for transmucosal administration, detergents and bile salts.
  • Transmucosal administration can be accomplished through the use of nasal sprays or suppositories.
  • the active compounds or tautomers thereof or a pharmaceutically acceptable salts or prodrugs of said compounds or tautomers typically are formulated into ointments, salves, gels, or creams as generally known in the art.
  • the active compounds or tautomers thereof or a pharmaceutically acceptable salts or prodrugs of said compounds or tautomers can be prepared with carriers that will protect the compound or tautomer thereof or a pharmaceutically acceptable salt or prodrug of said compound or tautomer against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • a controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, poly anhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
  • Liposomal suspensions can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound or tautomer thereof or a pharmaceutically acceptable salt or prodrug of said compound or tautomer calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound or tautomer thereof or a pharmaceutically acceptable salt or prodrug of said compound or tautomer and the therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound or tautomer thereof or a pharmaceutically acceptable salt or prodrug of said compound or tautomer for the treatment of individuals.
  • administration can be by periodic injections of a bolus, or can be made more continuous by intravenous, intramuscular or intraperitoneal administration from an external reservoir (e.g., an intravenous bag).
  • an external reservoir e.g., an intravenous bag
  • the composition can include the drug dispersed in a fibrinogen-thrombin composition or other bioadhesive.
  • the compound or tautomer thereof or a pharmaceutically acceptable salt or prodrug of said compound or tautomer then can be painted, sprayed or otherwise applied to the desired tissue surface.
  • the drugs can be formulated for parenteral or oral administration to humans or other mammals, for example, in effective amounts, e.g., amounts that provide appropriate concentrations of the drug to target tissue for a time sufficient to induce the desired effect.
  • pharmacogenomics i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug
  • Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug.
  • a physician or clinician can consider applying knowledge obtained in relevant pharmacogenomics studies in determining whether to administer a drug as well as tailoring the dosage and/or therapeutic regimen of treatment with the drug.
  • an effective amount of dosage of active compound or tautomer thereof or a pharmaceutically acceptable salt or prodrug of said compound or tautomer will be in the range of from about 0.01 to about 100 mg/kg of body weight/day.
  • the amount administered will also likely depend on such variables as the condition to be treated, the severity of the condition, the age and overall health status of the patient, the relative biological efficacy of the compound or tautomer thereof or a pharmaceutically acceptable salt or prodrug of said compound or tautomer delivered, the formulation of the compound or tautomer thereof or a pharmaceutically acceptable salt or prodrug of said compound or tautomer, the presence and types of excipients in the formulation, and the route of administration.
  • the initial dosage administered can be increased beyond the above upper level in order to rapidly achieve the desired tissue level or blood level, or the initial dosage can be smaller than the optimum.
  • Nonlimiting doses of active compound or tautomer thereof or a pharmaceutically acceptable salt or prodrug of said compound or tautomer comprise from about 0.1 to about 1500 mg per dose.
  • Nonlimiting examples of doses, which can be formulated as a unit dose for convenient administration to a patient include: about 0.1 mg, about 0.25 mg, about 0.5 mg, about 0.75 mg, about 1 mg, about 2.5 mg, about 5 mg, about 7.5 mg, about 10 mg, about 15, mg, about 20 mg, about 25 mg, about 50 mg, about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 500 mg, about 525 mg, about 550 mg, about 575 mg, about 600 mg, about 625 mg, about 650 mg, about 675 mg about 700 mg, about 725 mg, about 750
  • the present invention relates to a method composition or use further comprising an additional pharmaceutical agent, particularly, one or more compounds typically used for treating, preventing, or reducing the risk of an infection caused or mediated by Mycobacterium tuberculosis or nontuberculous mycobacteria and in particular those infections caused or mediated by resistant or highly virulent strains of mycobacteria.
  • an additional pharmaceutical agent particularly, one or more compounds typically used for treating, preventing, or reducing the risk of an infection caused or mediated by Mycobacterium tuberculosis or nontuberculous mycobacteria and in particular those infections caused or mediated by resistant or highly virulent strains of mycobacteria.
  • Nonlimiting examples of such compounds include, e.g., isoniazid, rifampin, rifapentine, rifabutin, ethambutol, pyrazinamide, cycloserine, ethionamide, levofloxacin, moxifloxacin, delafloxacin, nitroimidazoles like PA-824, mycobacterial gyrase inhibitors outside the quinolone class, riminophenazines, InhA inhibitors distinct from isoniazid, new generation diarylquinolines like TMC207, LeuRS inhibitors, tryptanthrins, inhibitors of mycobacterial glyoxylate pathway, non-rifamycin inhibitors of RNA polymerase, menaquinone biosynthesis inhibitors,
  • topoisomerase I inhibitors mycobacteterial protease inhibitors, gatifloxacin, ⁇ -aminosalicylic acid, streptomycin, amikacin, kanamycin, and capreomycin.
  • Vitamin B6 - Vitamin B6 can be used in combination with the compounds used in the present invention, as it is used for alleviating the associated numbness and tingling in the hands and feet.
  • NSAIDS non-steroidal anti- inflammatory drugs
  • the NSAIDS can be selected from the following categories: propionic acid derivatives; acetic acid derivatives; fenamic acid derivatives; biphenylcarboxylic acid derivatives; and oxicams. All of these NSAIDS are fully described in the U.S. Pat. No. 4,985,459 to Sunshine et al., issued Jan. 15, 1991, incorporated by reference herein.
  • propionic NSAIDS including but not limited to aspirin, acetaminophen, ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic acid, fluprofen and bucloxic acid.
  • steroidal anti-inflammatory drugs including hydrocortisone and the like.
  • compositions useful in the methods of the present invention can optionally comprise one or more surfactants.
  • the surfactants can be present at a level from about 0.1% to about 10%, alternatively from about 0.2% to about 5%, and yet alternatively from about 0.2% to about 2.5%.
  • Suitable surfactants include, but are not limited to, nonionic surfactants such as polyalkylene glycol ethers of fatty alcohols, and anionic surfactants such as taurates and alkyl sulfates.
  • nonionic surfactants such as polyalkylene glycol ethers of fatty alcohols
  • anionic surfactants such as taurates and alkyl sulfates.
  • Nonlimiting examples of these surfactants include isoceteth-20, sodium methyl cocoyl taurate, sodium methyl oleoyl taurate, and sodium lauryl sulfate. See U.S. Pat. No.
  • the oxazolidinone antibiotic compound or tautomer thereof or a pharmaceutically acceptable salt or prodrug of said compound or tautomer, equivalent to the desired delivery strength, e.g., 0.1 to 1500 mg per tablet) is premixed with 1/3 of the microcrystalline cellulose NF and 1/2 of the anhydrous lactose NF in a ribbon blender for 5 minutes at 20 RPM. To the premix is added the remaining 2/3 of the microcrystalline cellulose NF and the remaining 1/2 of the anhydrous lactose NF. This is blended for 10 minutes at 20 RPM. Crosscarmellose sodium is added to the blended powders and mixed for 5 minutes at 20 RPM. Finally the magnesium stearate is added to the mixture by passing through a 90 mesh screen and blended for an additional 5 minutes at 20 RPM. The lubricated mixture is compressed to provide tablets containing 0.1-1500 mg active ingredient per tablet.
  • Radezolid is a protein synthesis inhibitor that enters bacteria and binds to the 50S ribosomal subunit. Radezolid accumulates in the cytoplasm and lysosomes (not the
  • M. tuberculosis M. tuberculosis (MTB) is also an intracellular pathogen found in the lysosomes and cytoplasm of immune cells.
  • radezolid was tested for activity against MTB grown aerobically and in a low-oxygen recovery assay (LORA- a surrogate test for potency versus latent organisms). Given the favorable preclinical and clinical profiles of radezolid, especially its ability to concentrate in the lysosomes of infected macrophages, radezolid was tested for activity against M. tuberculosis.
  • MABA Antimicrobial activity was measured by MABA as reported (ref. 8). Briefly, MABA is a colorimetric assay using the color change of resazurin (from blue to pink) as an indicator of microbial growth.
  • Mycobacterium tuberculosis H37Rv H37Rv was grown in Middlebrook 7H9 broth medium supplemented with 0.2% (v/v) glycerol, 10% ADC (albumin, dextrose, catalase) and 0.05% Tween80. The bacteria were inoculated in lOOmL of 7H9 medium in 1L roller bottles and incubated, with turning, at 37°C in ambient air.
  • LORA was carried out in similar fashion according to published methods (ref. 9) using a luminescent strain of MTB grown under low oxygen conditions and frozen away at -80°C.
  • Radezolid was active in vitro, with an IC90 in the MABA of 0.03 ug/ml and 0.31 ug/ml in the LORA.
  • the MABA IC90 for isoniazid was 0.03 ug/ml.
  • Isoniazid was not active in the LORA.
  • Radezolid demonstrated an MIC value of 0.312 ⁇ g/ml against the drug- sensitive H37Rv strain and showed MICs ranging from ⁇ 0.078-0.312 ⁇ g/ml against clinical isolates of M. tuberculosis singlely resistant to the following antibiotics: streptomycin, isoniazid, kanamycin, ethionamide, ethambutol.
  • the MBC of radezolid against H37Rv was determined to be equal to the MIC (0.312 ⁇ g/ml).
  • radezolid reduced the bacterial load resulting from aerosol challenge with MTB by 1.96 loglO in the lungs and 2.58 loglO in the spleen.
  • the change in log cfu for isoniazid was -2.53 and -2.42 in the lungs and spleen, respectively.
  • Radezolid is highly potent against M. tuberculosis H37Rv.
  • Radezolid showed significant activity against the susceptible M. tuberculosis strain H37Rv. In the MABA, radezolid was more potent than comparator oxazolidinones, quinolones, and macrolides. Radezolid and another biaryloxazolidinone from the program (Compound A) had IC90 values similar to those collected for isoniazid. As shown in data from the LORA, when non-replicating cells were exposed to compound, drugs like isoniazid, ethambutol, and linezolid were not effective at inhibiting cell growth and recovery in aerobic conditions. Radezolid was the most active compound tested under these conditions, surpassing the activity of rifampicin and moxifloxacin.
  • radezolid represented the geometric mean value of three replicate experiments. Data for other compounds were the mean values from two test occasions, and rifampicin, ethambutol, and linezolid values were collected from the literature (refs. 8 and 9) or through personal communication with S. Franzlbau. Data with an asterisk were collected from experiments using 7H12 broth. Radezolid is highly active against MTB in vitro and in vivo. Radezolid is highly active in vitro against clinical and laboratory isolates of M. tuberculosis, using the inhibition of bacterial metabolism as a measure of antimycobacterial potency. In fact, radezolid activity is equal or superior to drugs that comprise the first line of therapy for tuberculosis patients (e.g. isoniazid, ethambutol, etc).
  • Radezolid is perhaps the most active compound tested in these studies for potency against organisms grown under hypoxic conditions.
  • the non-replicating/persistent state of bacteria grown under these in vitro conditions suggests that radezolid may have usefulness in treating latent infections.
  • the efficacy of radezolid was measured in a gamma-interferon knockout (GKO) mouse model (ref. 10).
  • the GKO mouse model was performed according to published methods and drugs were dosed orally: Radezolid at 50 mg/kg BID; isoniazid at 25 mg/kg QD. In vivo efficacy was measured using gamma interferon gene-disrupted mice as reported (ref. 10). Interferon gamma knockout mice (unable to control an infection of MTB) from a C57BL/6 background were infected in the standard manner (aerosol infection with the Erdman strain, utilizing the Glas-Col Inhalation Exposure System). Three mice were sacrificed Day 1 post-infection to determine bacterial uptake. Day 13 post-infection, 5 mice were sacrificed to determine bacterial load in the lungs and spleens.
  • mice administered via oral gavage began Day 13 post-infection and continued for 9 days. Day 22 post-infection the mice are sacrificed and bacterial loads are determined. An isoniazid control group, administered via oral gavage at 25 mg/kg/day was included in each study. Oxazolidinones were dosed orally at 50mg/kg BID in 0.5% Tween80, and 0.5% methylcellulose (in water).
  • Table 2 demonstrates that after establishing an infection in gamma interferon knock-out mice over the first thirteen days post inoculation, colony forming units of MTB Erdman reached approximately 6.6E7 and 9.7E3 in the lungs and spleen, respectively.
  • QD once daily
  • isoniazid colony counts were reduced 2.53 log 10 in lung compared the untreated controls on day 22.
  • Radezolid reduced cfu in the lung by nearly 2 loglO units, approaching 7.2E5 following twice daily (BID) dosing .
  • Radezolid also prevented MTB from spreading to and/or proliferating in the spleens of GKO mice, showing very similar activity to that of isoniazid.
  • Table 2. Radezolid is efficacious in the GKO Mouse Model

Abstract

L'invention concerne des méthodes de traitement des infections mycobactériennes, par exemple des infections causées ou induites par Mycobacterium tuberculosis ou par des mycobactéries non tuberculeuses et en particulier les infections causées ou induites par des souches résistantes ou hautement virulentes de mycobactéries, au moyen d'une quantité sûre et efficace d'un composé antibiotique.
PCT/US2011/034319 2010-04-28 2011-04-28 Méthode de traitement des infections mycobactériennes WO2011139832A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32877510P 2010-04-28 2010-04-28
US61/328,775 2010-04-28

Publications (2)

Publication Number Publication Date
WO2011139832A2 true WO2011139832A2 (fr) 2011-11-10
WO2011139832A3 WO2011139832A3 (fr) 2012-04-05

Family

ID=44904382

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/034319 WO2011139832A2 (fr) 2010-04-28 2011-04-28 Méthode de traitement des infections mycobactériennes

Country Status (1)

Country Link
WO (1) WO2011139832A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016077818A1 (fr) * 2014-11-14 2016-05-19 Melinta Therapeutics, Inc. Méthode de traitement, de prévention ou de réduction du risque d'une infection cutanée
US9944654B2 (en) 2014-10-22 2018-04-17 Merck Sharp & Dohme Corp. Nargenicin compounds and uses thereof as antibacterial agents
US20180280401A1 (en) * 2015-10-14 2018-10-04 The Global Alliance For Tb Drug Development, Inc. Combination antibacterial composition and short-course antibacterial regimen
US20190358206A1 (en) * 2016-05-17 2019-11-28 Melinta Subsidiary Corp. Topical formulations of biaryl heterocyclic compounds and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007133803A2 (fr) * 2006-05-15 2007-11-22 Rib-X Pharmaceuticals, Inc. Traitement d'infections mycobactériennes
WO2008085913A1 (fr) * 2007-01-04 2008-07-17 Rib-X Pharmaceuticals, Inc. Procédés pour traiter, prévenir, ou réduire le risque d'infections ophtalmiques, otiques, et nasales

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007133803A2 (fr) * 2006-05-15 2007-11-22 Rib-X Pharmaceuticals, Inc. Traitement d'infections mycobactériennes
WO2008085913A1 (fr) * 2007-01-04 2008-07-17 Rib-X Pharmaceuticals, Inc. Procédés pour traiter, prévenir, ou réduire le risque d'infections ophtalmiques, otiques, et nasales

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FORTUN J. ET AL.: 'Linezolid for the treatment of multidrug-resistant tuberculosis' JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY vol. 56, 2005, pages 180 - 185 *
SKRIPKIN, E. ET AL.: 'Rd-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance' ANTIMICROBIAL AGENTS AND CHEMOTHERAPY vol. 52, no. 10, 2008, pages 3550 - 3557 *
ZHOU, J. ET AL.: 'Design at the atomic level: Design of biaryloxazolidinones as potent orally active antibiotics' BIOORGANIC& MEDICINAL CHEMISTRY LETTERS vol. 18, 2008, pages 6175 - 6178 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9944654B2 (en) 2014-10-22 2018-04-17 Merck Sharp & Dohme Corp. Nargenicin compounds and uses thereof as antibacterial agents
US10144741B2 (en) 2014-10-22 2018-12-04 Merck Sharp & Dohme Corp. Nargenicin compounds and uses thereof as antibacterial agents
WO2016077818A1 (fr) * 2014-11-14 2016-05-19 Melinta Therapeutics, Inc. Méthode de traitement, de prévention ou de réduction du risque d'une infection cutanée
CN107205989A (zh) * 2014-11-14 2017-09-26 梅琳塔治疗公司 治疗、预防或降低皮肤感染风险的方法
US10471046B2 (en) 2014-11-14 2019-11-12 Melinta Subsidary Corp. Method for treating, preventing, or reducing the risk of skin infection
US20180280401A1 (en) * 2015-10-14 2018-10-04 The Global Alliance For Tb Drug Development, Inc. Combination antibacterial composition and short-course antibacterial regimen
US20190358206A1 (en) * 2016-05-17 2019-11-28 Melinta Subsidiary Corp. Topical formulations of biaryl heterocyclic compounds and methods of use thereof

Also Published As

Publication number Publication date
WO2011139832A3 (fr) 2012-04-05

Similar Documents

Publication Publication Date Title
US20190358206A1 (en) Topical formulations of biaryl heterocyclic compounds and methods of use thereof
JP6013734B2 (ja) キノロン化合物の製造方法
US9284325B2 (en) Spectinamides as anti-tuberculosis agents
JP6142076B2 (ja) 抗微生物性増強剤
US20190274978A1 (en) Antibacterial compositions
JP2017534654A (ja) 皮膚感染症を処置する、予防する、またはその危険性を低減するための方法
WO2011139832A2 (fr) Méthode de traitement des infections mycobactériennes
US20070249577A1 (en) Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
TW201806954A (zh) 抗微生物劑及製造與使用彼之方法
US20100004282A1 (en) Treatment of antibiotic-resistant bacteria infection
US20230105108A1 (en) Compounds for the treatment of bacterial infections and potentiation of antibiotics
WO2008085913A1 (fr) Procédés pour traiter, prévenir, ou réduire le risque d'infections ophtalmiques, otiques, et nasales
WO2007133803A2 (fr) Traitement d'infections mycobactériennes
US20210253589A1 (en) Aminomethylamidine and methylamidine antimicrobial compounds
WO2023022657A2 (fr) Découverte d'un inhibiteur de f-atp synthase pour le traitement de maladies de mycobacterium abscessus
US10717757B2 (en) Ketolides having antibacterial activity
US20240115521A1 (en) Compounds for the treatment of mycobacterial diseases
WO2008059261A1 (fr) Clotrimazole destiné au traitement d'infections par staphylocoques
AU2011332031B2 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11778008

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11778008

Country of ref document: EP

Kind code of ref document: A2